Concepedia

Author

Florence Giffard

Université de Caen Normandie

Also Known As

F Giffard, F. Giffard, Florence Giffard, Giffard, Florence

40

Publications

627

Citations

15

H-Index

21

Concepts

All Affiliations

Université de Caen NormandieCentre François BaclesseNormandie UniversitéInsermCancers et Préventions
FG

About

Florence Giffard is an author at Université de Caen Normandie specializing in ovarian cancer, medicine, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

187

2

Cell Biology

4

4

135

3

Obstetrics

3

3

74

4

Immunology

1

1

53

5

Pathology

1

1

29

Florence Giffard

×

17

Publications

582

Citations

15

H-Index

YearCitations

miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation

Christophe Denoyelle, Bernard Lambert, Matthieu Meryet‐Figuière,

Cell Death and Disease

2014

105

Downregulation of Bcl-x L and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy

Emilie Varin, Christophe Denoyelle, Émilie Brotin,

Carcinogenesis

2010

73

PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced

Abdelghani Jebahi, Marie Villedieu, Cécile Pétigny-Lechartier,

Cancer Letters

2014

53

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis

Karin Simonin, Monique N’Diaye, Stéphanie Lheureux,

APOPTOSIS

2013

39

Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells

Hubert Lincet, Perrine Kafara, Florence Giffard,

Journal of Ovarian Research

2013

39

Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids

Mégane Vernon, Bernard Lambert, Matthieu Meryet‐Figuière,

Molecular Cancer Therapeutics

2020

31

A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study

Florence Joly, Michel Fabbro, Philippe Follana,

Gynecologic Oncology

2022

31

Identification of predictive factors of response to the BH3‐mimetic molecule ABT‐737: An <i>ex vivo</i> experiment in human serous ovarian carcinoma

Stéphanie Lheureux, Monique N’Diaye, Cécile Blanc‐Fournier,

International Journal of Cancer

2014

29

Calcium signals inhibition sensitizes ovarian carcinoma cells to anti-Bcl-xL strategies through Mcl-1 down-regulation

Marie-Laure Bonnefond, Bernard Lambert, Florence Giffard,

APOPTOSIS

2015

28

Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma

Lucie Thorel, Pierre‐Marie Morice, Hippolyte Paysant,

Journal of Experimental & Clinical Cancer Research

2023

24

Page 1